The authors developed a mutation enhanced prognostic system consisting of adverse mutations including SF3B1, SRSF2, TP53, and U2AF1 in ET and SRSF2 in PV affecting OS, leukemia-free survival or myelofibrosis-free survival [186]. The gene discussed is U2AF1; the disease is essential thrombocythemia.